Hematological events and thyroid status in Imatinib treated CML Iraqi


  • Khaleed J. Khaleel




Background: Chronic myeloid leukemia (CML) is myeloproliferative of hematopoietic stem cells resulting in marked increased in granulocytes, platelets and red cells. Imatinib mesylate (IM) is potent tyrosine kinase inhibitor acts by occupying ATP binding site for BCR-ABL oncoprotein preventing phosphorylation of substrate and interrupting contact with protein. Aim of study: Evaluation of thyroid function and myelosuppresion induced by IM in CML patients. Materials and Methods: The study enrolled 13 patients with CML treated by IM for more than 6 months. Total blood count and blood film and thyroid function. Tests (T1 ,T4 and TSH) were performed. Results: All patients belong to Grade3 and Grade2 only of mylosuppresion, the most common cytopenia is neutropenia in (7) patients, anemia in (5) patients and only (4)patients having thrombocytopenia. Only three patients don’t achieve remission (6.6 %).Regarding thyroid function only one patient has high TSH level with normal T1 and T4. In spite of TSH level in patients significantly higher than the control group the mean values of two group were within normal range. Non-significant difference in T1 and T4 between the control and patients groups. Conclusion: IM do not seem to has clinically significant effect on thyroid function. However, thyroid function test is indicated before initiated of treatment with IM. Also CBC is highly recommended for monitoring CML patients on IM.






Cancer Research